



Company Announcement no. 37/2008

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, December 22, 2008

LifeCycle Pharma Announces Financial Calendar for 2009

LifeCycle Pharma A/S (OMX:LCP) announces the financial calendar for 2009:

- March 3, 2009: Release of Annual Report 2008.
April 23, 2009: Annual General Meeting
May 14, 2009: Interim Report for 1st Quarter - results from January 1 to March 31, 2009.
August 19, 2009: Interim Report for the 2nd Quarter – results from January 1 to June 30, 2009.
November 11, 2009: Interim Report for the 3rd Quarter – results from January 1 to September 30, 2009.

For more information, please contact:

LifeCycle Pharma A/S

Dr. Jim New

President & Chief Executive Officer

Phone: +45 7033 3300

Email: JSN@lcpharma.com

Peter Schøtt Knudsen

Head of Investor Relations

Phone: +45 7033 3300

E-mail: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose[®], can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide[™], currently on the U.S. market and a diversified near- and medium-term pipeline with five product candidates in clinical trials and one in preclinical development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.